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These Clinical Practice Guidelines (CPGs) have been
developed by Pakistan Society of Hepatology (PSH) and
Pakistan Society of Study of Liver Diseases (PSSLD).
Gastroesophageal variceal bleeding is a major compli-
cation of portal hypertension resulting from cirrhosis. It
occurs in 25 - 35 percent of patients with cirrhosis and
accounts for 80 - 90 percent bleeding episodes in these
patients. Up to 30% of initial bleeding episodes are fatal
and as many as 70% of survivors have recurrent
bleeding within one year.
Screening for varices:
Ideally, all patients should undergo screening upper
Gastrointestinal (GI) endoscopy for varices at the time of
initial diagnosis of cirrhosis. If patient have no varices,
repeat endoscopy should be done every 2 years in case
of compensated cirrhosis and annual in case of
decompensated cirrhosis. HVPG needs further study to
select patients for different therapies.
Pre-primary prophylaxis of varices:
Treatment of the underlying cause of cirrhosis should be
undertaken to prevent the development of portal hyper-
tension or reduce already developed portal hypertension
in an attempt to prevent the development of varices. At
present, β-blockers are not recommended to be used for
pre-primary prophylaxis of varices.
Primary prophylaxis of varices:
Patient with cirrhosis and small esophageal varices:
In high-risk small esophageal varices, Non-Selective
β-Blocker (NSBB) should be used. In low-risk small
esophageal varices, NSBB may be used if desired by
the treating physician. Nitrates alone or in combination
with NSBB are not recommended. Endoscopic Variceal
Band Ligation (EVBL) is not recommended in the
primary prophylaxis of small esophageal varices.
Repeat endoscopy should be done every 2 years in
case of compensated cirrhosis and annually in case of
decompensated cirrhosis.
Patients with cirrhosis and medium or large
esophageal varices: Primary Prophylaxis must be
given in the form of NSBB or EVBL. Choice of treatment
should be based on local resources and expertise,
physician/patient preference, side effects, and contra-
indications. Carvedilol is an emerging and effective
alternative β-blocker. Nitrates alone or with β-blockers
should not be used for primary prophylaxis of variceal
bleeding. There is no role of Endoscopic Injection
Sclerotherapy (EIS), TIPSS and/or shunt surgery.
Primary prophylaxis of gastric varices: The risk of
first bleeding from gastric varices is no greater than that
from esophageal varices. Data on the prevention of the
first bleeding in patients with gastric varices is sparse. It
is conceivable that beta-blocker therapy is equally
effective in this situation. The efficacy of cyanoacrylate in
these patients remains controversial.
Management of acute variceal bleeding:
Resuscitation: ICU management is recommended.
Endotracheal Tube (ET) intubation may be considered in
a patient if in shock, mental status change, continuous
heavy bleeding, and respiratory compromise.
Nasogastric (NG) tube may be placed in selected
patients with active bleeding for clearing the field of
vision and monitoring of continuous bleeding. Balloon
tamponade should only be used as a temporary ''bridge”
by trained personnel until definitive treatment can be
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instituted, for a maximum of 24 hours, and preferably in
an intensive care facility.
Blood volume replacement: Blood volume restitution
should be done cautiously and conservatively, using
plasma expanders to maintain hemodynamic stability
and packed red blood cells to maintain the hemoglobin
at approximately 7 - 8 g/dl, depending on other factors
such as patient's co-morbidities, age, hemodynamic
status and presence of ongoing bleeding clinically.
Colloids may be used cautiously while awaiting
availability of blood and blood products.
Vasoactive agents: In suspected variceal bleeding,
vasoactive agents should be started as soon as
possible, before endoscopy. The efficacy of Terlipressin
is equal to Octreotide as an adjuvant therapy for the
control of esophageal variceal bleeding and in-hospital
survival. In patients with esophageal variceal bleeding, a
24-hour course of Terlipressin is as effective as a
72-hour course when used as an adjunct to successful
EVBL. Pharmacological therapy alone may be
acceptable in circumstances where endoscopic facilities
are not available and patient has stopped bleeding with
this therapy. However, the patient should be referred for
endoscopy and definitive therapy (EVBL) as soon as
possible. At the primary care level, pharmacological
therapy should be started at the time of initial contact
with the patient.
Bacterial infections: Antibiotic prophylaxis is an
integral part of therapy for patients with cirrhosis
presenting with upper gastrointestinal bleeding and
should be instituted from admission. Intravenous
Ceftriaxone / oral quinolones are recommended for most
patients. Intravenous Ceftriaxone is preferable in
hospital settings with high prevalence of quinolone-
resistant bacterial infections and in patients on previous
quinolone prophylaxis.
Hepatic encephalopathy: Recommendations regarding
the management and prevention of encephalopathy in
patients with cirrhosis and upper GI bleeding cannot be
made on the basis of currently available data. It is best
left to the choice of caring physician.
Coagulopathy and thrombocytopenia: Recom-
mendations regarding management of coagulopathy
and thrombocytopenia cannot be made on the basis of
currently available data; it may be considered if the
platelets count is less than 50,000 /cmm. PT/INR is not
a reliable indicator of the coagulation status in patients
with cirrhosis.
Specific therapy: Patients with GI bleeding and
features suggesting cirrhosis should have upper
endoscopy as soon as possible after admission (within
12 hours) after hemodynamic stabilization with airway
control. Endoscopic therapy is recommended in any
patient who presents with documented upper GI
bleeding and in whom esophageal varices are the cause
of bleeding. Endoscopic Variceal Band Ligation (EVBL)
is the recommended form of endoscopic therapy for
acute esophageal variceal bleeding, although
sclerotherapy may be used in acute setting if ligation is
technically difficult. Endoscopic Injection Sclerotherapy
(EIS) with tissue adhesive (e.g. N-butyl-cyanoacrylate)
is recommended for acute bleeding from Isolated
Gastric Varices (IGV) and those Gastro-Esophageal
Varices type-2 (GEV-2) that extend beyond the cardia.
EVBL or EIS with tissue adhesive can be used in
bleeding from Gastroesophageal Varices type-1 (GEV-1).
Combination of pharmacological and endoscopic
therapy is the most rational approach in the treatment of
acute variceal hemorrhage.
Early TIPSS: An early TIPSS within 72 hours (ideally 24
hours) should be considered in patients at high-risk of
treatment failure (e.g. CTP class C <14 points or CTP
class B, or with active bleeding) after initial pharma-
cological and endoscopic therapy. HVPG measurements
may be helpful to select patients for early TIPSS.
Treatment failures:
Refractory bleeding: Persistent bleeding despite
combined pharmacological and endoscopic therapy is
best managed by TIPSS with PTFE-covered stents.
Balloon tamponade should only be used in massive
bleeding as a temporary bridge until definitive treatment
can be instituted (for a maximum of 24 hours, preferably
in an intensive care facility). Surgery may be considered
in the absence of facilities for TIPS in select patients
(child A cirrhosis with acute, uncontrolled variceal
bleeding). Emergency surgical portocaval shunt (within
8 hours of onset of bleeding) has been reported to be
associated with almost universal control of bleeding and
a low mortality over a 30-year period.Uncontrolled data
suggest that self-expanding covered esophageal metal
stents may be an option in refractory esophageal
variceal bleeding, although further evaluation is needed.
Re-bleeding:
During the first 5 days it may be managed by a second
attempt at endoscopic therapy. If re-bleeding is severe,
PTFE-covered TIPSS is likely the best option.
Secondary prophylaxis of varices:
After the control of acute variceal bleeding, secondary
prophylaxis must be given to all patients. Patients who
required shunt surgery/TIPSS to control the acute
episode do not require further preventive measures. All
these patients should be referred to a transplant center,
if they are otherwise a candidate (i.e., CTP score ≥ 7 or
a MELD score ≥ 15).
Secondary prophylaxis should be started as soon as
possible from day 6 of the index variceal bleeding
episode or at the time of discharge. Combination NSBB
and endoscopic variceal ligation is the treatment of
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choice for secondary prophylaxis. If endoscopy is not
possible, BB alone or in combination with ISMN should
be given. If BB are contraindicated then EVL is the
preferred treatment.
Propranolol and Nadolol have been extensively studied;
however Carvedilol is an emerging alternative.
Carvedilol may be started at a dose of 6.25 mg daily and
increased to 6.25 mg twice daily, if clinically tolerated.
Carvedilol is as effective as Nadolol plus Isorsorbide-5-
Mononitrate in the prevention of gastroesophageal
variceal rebleeding with fewer severe adverse events
and similar survival.
EVBL should be repeated every 2 - 4 weeks until
obliteration. Following successful eradication of varices,
patients should be endoscoped at three months and six
months intervals thereafter to look for recurrence of
varices. In case of recurrence, band ligation should be
repeated.
TIPSS may be considered in Child A or B patients who
have recurrent variceal bleed despite combination of
pharmacological and endoscopic therapy as secondary
prophylaxis. Surgical shunts may be considered in
Child A / selected Child B patients as an alternative, if
TIPSS is unavailable. Transplantation provides good
long term outcome in appropriate candidates and should
be considered. TIPSS may be used as a bridge to
transplantation.
Treatment of GEV-1 by EVL or BB is sufficient. GEV-1
may be treated with cyanoacrylate injection. After the
acute episode, patients with GEV-2/IGV-1 should receive
beta blockers along with repeated sessions of CA
injection or TIPSS. There is a lack of good quality data
to establish the actual place of BRTO in the secondary
prophylaxis bleeding from GV. BB should be used for
prevention of recurrent bleeding in portal hypertensive
gastropathy.
Clinical practice guidelines on the management of variceal bleeding
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INTRODUCTION
Gastroesophageal variceal bleeding is a major
complication of portal hypertension (HTN) resulting from
cirrhosis. It occurs in 25 - 35% of patients with cirrhosis
and accounts for 80 - 90% bleeding episodes in these
patients.1-3 Variceal bleeding is associated with greater
morbidity and mortality than other causes of gastro-
intestinal bleeding, as well as higher economic burden.4-
6 Upto 30% of initial bleeding episodes are fatal and as
many as 70% of survivors have recurrent bleeding within
one year.1,7 Therefore, one-year survival rate after
variceal bleeding is poor, ranging from 32 to 80%.7,8
There have been numerous advances in the manage-
ment of variceal bleeding in patients with cirrhosis. Many
milestones, review articles and guidelines including UK
Guidelines,9 OMGE Guidelines,10 AASLD,11 Baveno,12
PSG Guidelines-2006,13 etc., have been published to
suggest the evidence-based appropriate management
of patients with variceal bleeding.
Gastroenterologists/Hepatologists face some unique
challenges in Pakistan regarding the management of
variceal bleeding. Prevalence of hepatitis and liver
cirrhosis and its associated complications are still on
rise. There seems to be a major chunk of unrecognized
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ABSTRACT
Gastroesophageal variceal bleeding occurs in 30 - 50% of patients of liver cirrhosis with portal hypertension, with 20-70%
mortality in one year. Therefore, it is essential to screen these patients for varices and prevent first episode of bleeding by
treating them with β-blockers or endoscopic variceal band ligation. Ideally, the patients with variceal bleeding should be
treated in a unit where the personnel are familiar with the management of such patients and where routine therapeutic
interventions can be undertaken. Proper management of such patients include: initial assessment, resuscitation, blood
volume replacement, vasoactive agents, prevention of associated complications such as bacterial infections, hepatic
encephalopathy, coagulopathy and thrombocytopenia, and specific therapy. Rebleeding occurs in about 60% patients
within 2 years of their recovery from first variceal bleeding episode, with 33% mortality. Therefore, it is mandatory that all
such patients must be started on combination of β-blockers and band ligation to prevent recurrence of bleeding. Patients
who required shunt surgery/TIPSS to control the acute episode do not require further preventive measures. These clinical
practice guidelines (CPGs) have been jointly developed by Pakistan Society of Hepatology (PSH) and Pakistan Society
of Study of Liver Diseases (PSSLD).
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cases of liver cirrhosis in the community. Access to
health care is only patchy and very limited. There is lack
of adequate diagnostic facilities including endoscopic
equipment, and moreover cost of accessories and
maintenance costs are extremely high. There is a lack of
human resource (HR), capable of recognizing the
severity of the problem and risk stratification - which
determines the referral pattern. There is a lack of
applicability of the current prognostic systems and
development of new systems. The availability and safety
of blood products is questionable. Training slots are
deficient for healthcare workers. Awareness of general
principles of resuscitation with a local twist to these is
highly needed. Issues are being encountered with
Sengstaken-Blakemore tube. Patient's attitude towards
specialized care is a hurdle in delivering the best
treatment. There is a lack of affordability on patients'
part. Issues are encountered regarding more definitive
therapies for cirrhotic patients including liver transplant
(LT) and transvenous intrahepatic portosystemic shunt
(TIPSS).
Keeping in view these challenges, limited resources and
multifaceted healthcare system, there is an utmost need
to develop clinical practice guidelines (CPGs) to provide
a data-supported approach to the management of
patients with varices and variceal hemorrhage in
Pakistan.
Management of ectopic varices, Portal Hypertensive
Gastropathy (PHG) and Gastric Antral Vascular Ectasia
(GAVE) are beyond the scope of these guidelines as
these are focusing on esophageal and gastric varices
and not all bleedings related to portal hypertension.
METHODOLOGY
Eminent experts from all over the country kindly
consented to attend the meeting to develop Clinical
Practice Guidelines (CPGs) with aims to define key
events in variceal bleeding, to review the existing
evidence on the natural history, the diagnosis and the
therapeutic modalities of variceal bleeding, and to make
evidence-based recommendations for the management
of patients with variceal bleeding in Pakistan. Three
working committees were made in advance to review
literature and make guidelines on the pre-primary and
primary prophylaxis of variceal bleeding, management
of acute variceal bleeding, and secondary prophylaxis
of variceal bleeding. All the experts agreed upon to
adopt Oxford System of Grading of Evidence and
Recommendations13 for drafting these CPGs.
In September 2013, all the relevant global and local
literature including review articles, guidelines, statements
and original research data were reviewed in a meeting
to draft these CPGs. The available evidence was
graded according to the criteria given in Table I. All
recommendations for clinical practice were graded
according to the criteria given in Table II. After the
meeting, the final draft was sent to all the members for
final review and approval.
Objectives of the guidelines: These guidelines were
formulated to provide a data-supported approach
towards management of variceal bleeding in Pakistan.
These are preferred approaches to the diagnostic,
therapeutic and preventive aspects of care. These are
intended to be flexible; in contrast to standards of care,
which are inflexible policies to be followed in every case.
Target population: These guidelines are applicable to
patients of liver cirrhosis with portal hypertension with or
without esophageal and/or gastric varices.
Target users: These guidelines are developed for all
segments of healthcare involved in the evaluation and
management of cases with variceal bleeding, including
hospitals, all levels of healthcare providers, i.e. primary
level - individuals and facilities, secondary level -
regional hospitals with and without endoscopy facilities
and other support facilities, tertiary level - having
endoscopic facility, intensive care facility, hepatobiliary
surgery, and transplant facility, etc.; policy makers/
administrators, and patients.
DISCUSSION
Portal hypertension: Portal hypertension is a progressive
complication of cirrhosis, regardless of its etiology. Portal
hypertension results from the combination of increased
intra-hepatic vascular resistance and increased blood
flow through the portal venous system.15-17
Hepatic Venous Pressure Gradient (HVPG), which is the
difference between the wedged (or occluded) hepatic
venous pressure and the free hepatic venous pressure,
is a fair estimate of portal hypertension.18 Normal HVPG
is 3 - 5 mmHg. Portal HTN is defined as HVPG of more
than 5 mmHg. Clinically significant portal hypertension is
defined as HVPG of 10 mmHg or more.19
Natural history of varices: Patients with liver cirrhosis
and portal hypertension develop two types of varices
depending upon the site of occurrence: esophageal
varices and/or gastric varices.
When cirrhosis is first diagnosed, esophageal varices
are present in ~40% of compensated and 60% of
decompensated patients.20 In cirrhotic patients without
varices at first endoscopy, the rate of development is
approximately 8% per year.21 In patients with evidence
of varices, progression from small varices to medium or
large varices occurs at an average rate of 8 % per year
(5 - 12% at 1 year and 31% at 3 years).22 The rate of
progression may be higher (22 vs. 2%) in the presence
of any of the following factors: higher Child-Pugh-
Turcotte (CTP) class, alcohol-related cirrhosis, and high-
risk stigmata of bleed (e.g., red wale marks).21 The
annual risk of bleeding from esophageal varices is
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5 - 15% depending on the size of varices. Bleeding risk
is higher among persons with small varices, as
compared with persons without varices (12 vs. 2%).21
The highest annual risk of bleeding within the first year
occurs in persons with large varices.23 The predictors of
bleeding include presence of decompensated cirrhosis
(CTP class B or C), size of varices, and presence
of high-risk stigmata upon endoscopy (red wale
Clinical practice guidelines on the management of variceal bleeding
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Table I: Oxford centre for evidence-based medicine levels of evidence.
Therapy / prevention, 
aetiology / harm
SR (with homogeneity*) of
RCTs.
Individual RCT (with narrow
Confidence Interval‡).
All or none§
SR (with homogeneity*) of
cohort studies.
Individual cohort study
(including low quality RCT;
e.g., <80% follow-up).
"Outcomes" Research;
Ecological studies.
SR (with homogeneity*) of
case-control studies.
Individual case-control study.
Case-series (and poor
quality cohort and case-
control studies§§).
Expert opinion without
explicit critical appraisal, or
based on physiology, bench
research or "first principles"
Prognosis
SR (with homogeneity*) of
inception cohort studies;
CDR† validated in different
populations.
Individual inception cohort
study with > 80% follow-up;
CDR† validated in a single
population.
All or none case-series
SR (with homogeneity*) of
either retrospective cohort
studies or untreated control
groups in RCTs.
Retrospective cohort study
or follow-up of untreated
control patients in an RCT;
derivation of CDR† or
validated on split-sample§§§
only.
"Outcomes" Research 
Case-series (and poor
quality prognostic cohort
studies***).
Expert opinion without
explicit critical appraisal, or
based on physiology, bench
research or "first principles"
Diagnosis
SR (with homogeneity*) of 
Level 1 diagnostic studies; 
CDR† with 1b studies from 
different clinical centres.
Validating** cohort study 
with good††† reference 
standards; or CDR† tested 
within one clinical centre.
Absolute SpPins and 
SnNouts††
SR (with homogeneity*) of 
Level >2 diagnostic studies.
Exploratory** cohort study 
with good††† reference 
standards; CDR† after 
derivation, or validated only 
on split-sample§§§ or 
databases.
SR (with homogeneity*) of 
3b and better studies.
Non-consecutive study; 
or without consistently 
applied reference standards.
Case-control study, poor or 
non-independent reference 
standard.
Expert opinion without explicit
critical appraisal, or based on
physiology, bench research
or "first principles"
Differential diagnosis/
symptom prevalence study
SR (with homogeneity*) of
prospective cohort studies.
Prospective cohort study
with good follow-up****
All or none case-series.
SR (with homogeneity*) of
2b and better studies.
Retrospective cohort study,
or poor follow-up.
Ecological studies.
SR (with homogeneity*) of
3b and better studies.
Non-consecutive cohort
study, or very limited
population.
Case-series or superseded
reference standards.
Expert opinion without
explicit critical appraisal, or
based on physiology, bench
research or "first principles"
Economic and decision
analyses
SR (with homogeneity*) of
Level 1 economic studies.
Analysis based on clinically
sensible costs or
alternatives; systematic
review(s) of the evidence;
and including multi-way
sensitivity analyses.
Absolute better-value or
worse-value analyses ††††
SR (with homogeneity*) of
Level >2 economic studies. 
Analysis based on clinically
sensible costs or
alternatives; limited review(s)
of the evidence, or single
studies; and including multi-
way sensitivity analyses.
Audit or outcomes research.
SR (with homogeneity*) of
3b and better studies.
Analysis based on limited
alternatives or costs, poor
quality estimates of data, but
including sensitivity analyses
incorporating clinically
sensible variations.
Analysis with no sensitivity
analysis.
Expert opinion without
explicit critical appraisal, or
based on economic theory
or "first principles"
Level
1a
1b
1c
2a
2b
2c
3a
3b
4
5
Notes:
* By homogeneity we mean a systematic review that is free of worrisome variations (heterogeneity) in the directions and degrees of results between individual studies. Not all systematic 
reviews with statistically significant heterogeneity need be worrisome, and not all worrisome heterogeneity need be statistically significant. As noted above, studies displaying 
worrisome heterogeneity should be tagged with a "-" at the end of their designated level.
† Clinical Decision Rule. (These are algorithms or scoring systems that lead to a prognostic estimation or a diagnostic category.)
‡ See note above for advice on how to understand, rate and use trials or other studies with wide confidence intervals.
§ Met when all patients died before the Rx became available, but some now survive on it; or when some patients died before the Rx became available, but none now die on it.
§§ By poor quality cohort study we mean one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded), objective 
way in both exposed and non-exposed individuals and/or failed to identify or appropriately control known confounders and/or failed to carry out a sufficiently long and complete follow-
up of patients. By poor quality case-control study we mean one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same 
(preferably blinded), objective way in both cases and controls and/or failed to identify or appropriately control known confounders.
§§§ Split-sample validation is achieved by collecting all the information in a single tranche, then artificially dividing this into "derivation" and "validation" samples.
†† An "Absolute SpPin" is a diagnostic finding whose Specificity is so high that a Positive result rules-in the diagnosis. An "Absolute SnNout" is a diagnostic finding whose Sensitivity is so 
high that a Negative result rules-out the diagnosis.
‡‡ Good, better, bad and worse refer to the comparisons between treatments in terms of their clinical risks and benefits.
††† Good reference standards are independent of the test, and applied blindly or objectively to applied to all patients. Poor reference standards are haphazardly applied, but still 
independent of the test. Use of a non-independent reference standard (where the 'test' is included in the 'reference', or where the 'testing' affects the 'reference') implies a level 4 study.
†††† Better-value treatments are clearly as good but cheaper, or better at the same or reduced cost. Worse-value treatments are as good and more expensive, or worse and the equally or 
more expensive.
** Validating studies test the quality of a specific diagnostic test, based on prior evidence. An exploratory study collects information and trawls the data (e.g. using a regression analysis) 
to find which factors are 'significant'.
*** By poor quality prognostic cohort study we mean one in which sampling was biased in favour of patients who already had the target outcome, or the measurement of outcomes was 
accomplished in <80% of study patients, or outcomes were determined in an unblinded, non-objective way, or there was no correction for confounding factors.
**** Good follow-up in a differential diagnosis study is >80%, with adequate time for alternative diagnoses to emerge (for example 1-6 months acute, 1 - 5 years chronic).
 
marks/cherry red spots).24 The 1-year rate of recurrent
variceal hemorrhage is approximately 60%.25 The
6-week mortality with each episode of variceal
hemorrhage is approximately 15 - 20%.26
Gastric varices are less prevalent than esophageal
varices, and account for approximately 20 - 30% of
cases of variceal bleeding. The prevalence of gastric
varices in patients with portal hypertension varies from
6 - 78% and approximately 25% of gastric varices bleed
during lifetime, with a higher bleeding incidence for
fundal varices.27 Gastric varices occur five times more
often in patients with esophageal varices that have
previously bled than in those that have never bled.
Although gastric variceal haemorrhage occurs less
frequently than esophageal variceal haemorrhage, the
severity of bleeding and mortality, especially with fundal
varices, is greater. Risk factors for gastric variceal
haemorrhage include the size of fundal varices-large,
medium, small (defined as 10 mm, 5 - 10 mm, and
< 5 mm, respectively), CTP class (C,B,A), and
endoscopic presence of variceal red spots (defined as
localized reddish mucosal area or spots on the mucosal
surface of a varix).28
Classification of varices: Esophageal varices are
classified into small, medium and large esophageal
varices1 as detailed below (Figure 1):
Small varices generally defined as minimally elevated
veins above the esophageal mucosal surface, medium
varices defined as tortuous veins occupying less than
one-third of the esophageal lumen, and large varices
defined as those occupying more than one-third of the
esophageal lumen.
Gastric varices are classified into: 1) Primary and
secondary gastric varices according to timing of
appearance; and (2) Gastroesophageal Varices (GEV) -
1 and 2, and Isolated Gastric Varices (IGV) - 1 and 2,
according to their relationship with esophageal varices
and their location in the stomach (Figure 2).26 Primary
gastric varices are those detected at the time of the first
endoscopy, whereas secondary gastric varices are
those which occur within two years of eradication of
esophageal varices.
Gastroesophageal varices-1 are those which are
connected with esophageal varices and are located on
the lesser curvature.
Gastroesophageal varices-2 are those which are
connected with esophageal varices and are located in
the fundus.
Isolated gastric varices-1 are those which are not
connected with esophageal varices and are located in
the fundus.
Isolated gastric varices-2 are those which are located in
the stomach outside the fundus and even in the first part
of duodenum.
Screening for varices: There are two ways to screen
for varices including upper Gastrointestinal (GI)
endoscopy and non-endoscopic parameters.
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Table II: Grades of recommendation.
A Consistent level 1 studies. 
B Consistent level 2 or 3 studies or extrapolations from level 1 studies.
C Level 4 studies or extrapolations from level 2 or 3 studies. 
D Level 5 evidence or troublingly inconsistent or inconclusive studies of any level.
"Extrapolations" are where data is used in a situation that has potentially clinically important
differences than the original study situation.
Figure 1: Classification of esophageal varices.
Figure 2: Sarin's classification of gastric varices.
GEV1 = Gastro-Esophageal Varix 1
GEV2 = Gastro-Esophageal Varix 2
IGV1 = Isolated-Gastric Varix 1 
IGV2 = Isolated-Gastric Varix 2
Figure 3: Management of acute variceal bleeding.
Many studies suggest that all patients should undergo
an screening upper GI endoscopy at the time of initial
diagnosis of cirrhosis for esophageal and gastric
varices.22,23 As mentioned before, Pakistan has
restricted resources and most patients are poor;
therefore, at present it cannot be made mandatory for all
patients to undergo screening upper GI endoscopy at
the time of diagnosis of cirrhosis.
Non-endoscopic parameters include platelets count,
presence of splenomegaly, ratio of platelets count and
splenomegaly, increased portal vein diameter > 13 mm,
and more recently Transient Elastography (TE) by
Fibroscan. All of these have been suggested to be useful
in selecting patients with a high risk of having large
esophageal varices. However, absence of these tests,
alone or in combination, is not accurate enough to
completely discard the presence of esophageal
varices.23,29,30 Abbasi et al. found in their observational
study that platelet count was significantly and inversely
correlated with the grade of esophageal varices.31
Recently Sharma et al. found that measurement of
spleen stiffness can differentiate large vs. small varices
and non-bleeder versus bleeder.32 However, all these
non-endoscopic parameters need to be evaluated
further by local studies.
Recommendations:
1. Ideally, all patients should undergo screening upper
GI endoscopy at the time of initial diagnosis of cirrhosis
for varices (1a; A).
2. If patient have no varices, repeat endoscopy should
be done: (a) Every 2, years in case of compensated
cirrhosis (5; D); (b) Annual, in case of decompensated
cirrhosis (5; D).
3. HVPG needs further study to select patients for
different therapies (5; D)
Pre-primary prophylaxis of varices: Pre-primary
prophylaxis means prevention of the development of
varices. In patients who do not have gastroesophageal
varices, there has been no difference between placebo
and β-blockers (BB) in the prevention of development of
varices. Serious adverse events were more common
among patients in the β-blockers group.33 Therefore,
treatment with non-selective β-blockers (NSBB) is not
recommended in this setting. The main focus at this
stage is to treat the underlying cause of cirrhosis which
will reduce portal hypertension and may prevent the
development of clinical complications.23,34 This includes
abstinence in alcoholics, anti-viral in viral cirrhosis,
lifestyle changes in non-alcoholic steatohepatitis
(NASH), corticosteroids in autoimmune hepatitis,
phlebotomies in hemochromatosis, copper chelating
agents in Wilson's disease and use of ursodeoxycholic
acid (UDA) in primary biliary cirrhosis. Surveillance
endoscopies should be performed every 2 years in these
patients; and annually, if decompensation occurs.35
HVPG measurement needs further studies to select
treatment in patients without varices.
Recommendations:
1. Treatment of the underlying cause of cirrhosis should
be undertaken to prevent the development of portal
hypertension or reduce already developed portal
hypertension in an attempt to prevent the development
of varices (1a; A).
2. At present, β-blockers are not recommended to be
used in pre-primary prophylaxis of varices (1b; A).
Primary prophylaxis of varices: In chronic liver
disease, 30 - 50% of patients with portal hypertension
will bleed from varices and about 50% will die from the
effects of the first bleed.24,36-39 Thus, to prevent the first
episode of bleeding seems essential. Non-selective
β-blockers with or without nitrates and endoscopic
variceal band ligation (EVBL) have been used for the
primary prophylaxis of variceal bleeding.22,40
Patient with cirrhosis and small Esophageal varices:
Small esophageal varices are of two types: 
1. Low-risk small esophageal varices; (a) Small
esophageal varices in cirrhosis CTP class A; (b) Small
esophageal varices in cirrhosis CTP class B or C, but
without any red wale marks or cherry red spots.
2. High-risk small esophageal varices: (a) Small
esophageal varices in cirrhosis CTP class A, and having
red wale marks or cherry red spots; (b) Small
esophageal varices in cirrhosis CTP class B or C
A large multicenter, placebo-controlled trial reported that
patients with small varices treated with Nadolol had a
significantly slower progression to large varices (11% at
3 years) than patients who were randomized to placebo
(37% at 3 years), with no differences in survival.41 In
patients with low risk small esophageal varices, long-
term benefits of the use of non-selective β-blockers
(NSBB) are not well established. In patients with high
risk small esophageal varices, treatment with non-
selective β-blockers is strongly recommended.23
However, patients who are not candidates for non-
selective β-blockers therapy, surveillance endoscopy is
recommended every two years and annually in those
with hepatic decompensation.22 HVPG, wherever
available, can be utilized to stratify patients as
responders and non-responders in a single procedure
using intravenous Propranolol to reduce or abolish the
risk of first variceal bleed. A meta-analysis of
10 randomized controlled trials evaluating isosorbide
mononitrate (ISMN) alone or with non-selective
β-blockers showed no beneficial effects in the primary
prophylaxis of esophageal varices.42 EVBL is not
recommended for the primary prophylaxis of small
varices.35
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Recommendations:
1. In high-risk small esophageal varices, NSBB should
be used. In low-risk small esophageal varices, NSBB
may be used if desired by the treating physician. Nitrates
alone or in combination with NSBB not recommended
(1b;A)
2. EVBL is not recommended in the primary prophylaxis
of small esophageal varices (5; D).
3. Repeat endoscopy should be done: (a) Every two
years in case of compensated cirrhosis (III;C);
(b)  Annual in case of decompensated cirrhosis (III;C)
Patients with cirrhosis and medium or large
esophageal varices: Primary prophylaxis with non-
selective β-blockers and endoscopic variceal band
ligation (EVBL) has been shown independently to
decrease the risk of a first episode of variceal
bleeding.20,43 A systematic review of 19 randomized
trials found a beneficial effect of band ligation on
primary prevention of upper gastrointestinal bleeding in
patient with esophageal varices.44 A meta-analysis of
12 randomized controlled trials evaluating the role of
non-selective β-blockers and EVBL detected no
significant difference in the incidence of gastrointestinal
bleeding (EVBL 16.37% versus β-blockers 20.50%; RR
0.79 [95% CI 0.61 to 1.02]; RR reduction -21%
[95% CI_39% to 2%]; p=0.07), showing that EVBL and
β-blockers therapy were equally effective in the primary
prevention of bleeding.45 Three randomized controlled
trials have investigated the efficacy of propranolol and
EVBL in patients with high-risk esophageal varices. In
these studies EVBL of the varices is safe and more
effective than propranolol for the primary prevention of
variceal bleeding, but not mortality.46-48 For EVBL in
primary prophylaxis, recommended intervals between
two sessions should be 2-4 weeks.49 Endoscopic
injection sclerotherapy (EIS), TIPSS and shunt surgery
have not been advocated for primary prophylaxis so far.
Choice of non-selective β-blockers in primary
prophylaxis: Propranolol, nadolol and more recently,
carvedilol have been extensively studied for use as
primary prophylaxis of gastro-esophageal variceal
hemorrhage. For effective β-blockade, dose should be
adjusted to the maximal tolerated dose (25% reduction
in heart rate from baseline or heart rate upto 55
beats/minute or systolic blood pressure upto 90 mmHg).
However, this does not establish responder or non-
responder status of the patient. The adverse
reactions reported with non-selective β-blockers are
shortness of breath, nausea, vomiting, hypotension, and
impotence. Twenty-five percent of the patients have
contraindications to β-blockers and discontinuation rate
is ~15% of patients. Two studies investigated the role of
carvedilol in the primary prophylaxis as compared to
propranolol and EVBL, both studies showed that
carvedilol is an effective and better option for primary
prophylaxis in patients with high-risk esophageal varices
and it is found to be superior in achieving an adequate
HVPG response (a HVPG reduction of ≥ 20% of baseline
or ≤ 12 mmHg) as compared to propranolol.50, 51 In a
recent study from Karachi, carvedilol was found to be as
effective as EVBL for the prevention of first variceal
bleed in cirrhotic patients with no difference in mortality
between groups. Non-selective β-blockers should be
continued indefinitely.52
Recommendations:
1. Primary Prophylaxis must be given in the form of
NSBB or EVBL (1a; A); (a) Choice of treatment should
be based on local resources and expertise,
physician/patient preference and side effects, and
contra-indications (5; D); (b) Carvedilol is an emerging
and effective alternative β-blocker (1b; A); (c) Nitrates
alone or with    β-blockers should not be used for primary
prophylaxis of variceal bleeding (Ia; A).
2. There is no role of EIS, TIPSS and/or Shunt Surgery
(1a; A)
Primary prophylaxis of gastric varices: Data on
prevention of the first bleeding in patients with gastric
varices is sparse. It is conceivable that beta-
blocker therapy is equally effective in this situation. The
efficacy of cyanoacrylate in these patients remains
controversial.53
Management of acute variceal bleeding: Variceal
haemorrhage is typically an acute clinical event,
characterized by severe gastrointestinal bleeding
presenting as hematemesis with or without melena or
hematochezia. Hemodynamic instability, tachycardia
and hypotension are common. A successful outcome, as
in all cases of gastrointestinal bleeding, hinges on
prompt resuscitation, hemodynamic support, and
correction of hemostatic dysfunction, preferably in an
ICU. After stabilizing the patient hemodynamically, one
should focus on the differential diagnosis. Although
variceal bleeding is common in patients with cirrhosis
who have acute upper GI haemorrhage, other causes of
bleeding, such as ulcer disease, must be considered.
Empirical pharmacological therapy is indicated in
situations in which variceal bleeding is likely.
Subsequently, endoscopy facilitates an accurate
diagnosis and endoscopic therapy. Specific
management varies according to the source of variceal
bleeding: esophageal varices or gastric varices.
There are no satisfactory non-endoscopic indicators of
the presence of varices. While further studies are
awaited, endoscopic screening is still the best practice to
detect varices. The hepatic vein pressure gradient
(HVPG) is presently the most reliable predictor of
variceal development;10 anyhow, it is still not widely used
in clinical practice. Therefore, short of endoscopy,
detailed history and good physical examination remain
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the most reliable tool to make the probable diagnosis of
variceal bleeding. Source of upper GI bleed may be
considered as variceal if:
Patient is a diagnosed case of liver cirrhosis or non-
cirrhotic portal hypertension.
No other cause like NSAIDs, peptic ulcer disease, etc. is
suggested by the history.
Signs of liver cirrhosis and/or portal hypertension are
present.
Definitions in the context of acute variceal bleeding:
The committee adopted the following definitions in the
context of acute variceal bleeding:
Variceal bleeding: Bleeding from an esophageal or
gastric varix at the time of endoscopy or the presence of
large esophageal or gastric varices with blood in the
stomach and no other recognizable cause of bleeding9
and in case of absence of blood presence of esophageal
or gastric varices with evidence of recent bleed in the
form of cherry red spots and/or red wale marks.
Clinically significant bleeding: When there is a
transfusion requirement of 2 units of blood or more
within 24 hours of the time zero, together with a systolic
blood pressure of less than 100 mm of Hg or a postural
change of greater than 20 mm Hg and /or pulse rate
greater than 100 beats per minute at time zero. Time
zero is the time of admission to the first hospital the
patient is taken to.9
Timeframe of acute bleeding: Acute bleeding is
represented by an interval of 120 hours (5 days) from
time zero.12 Any bleeding occurring during this time
interval is considered as failure to control bleeding. Any
evidence of bleeding after 120 hours is the first
rebleeding.
Failure to control bleeding: The definition of failure to
control bleeding is divided into two timeframes.9
Within six hours: Any of the following factors:
Transfusion requirement of 4 units or more.
Inability to achieve an increase in systolic blood
pressure by 20 mm Hg or to 70 mm Hg or more.
Inability to achieve a pulse rate, reduction to less than
100 beat per minute.
Reduction of 20 beat /minute from baseline pulse rate.
After six hours: Any of the following factors:
Occurrence of haematemesis from the 6-hour point.
Reduction in blood pressure of more than 20 mm Hg
from the 6-hours point.
Increase in pulse rate of more than 20 beats per minute
from the 6-hour point on two consecutive readings an
hour apart.
Transfusion of 2 units of blood or more (over and above
the previous transfusions) required to increase the
hematocrit to above 27% or hemoglobin to above 9 g/dl.
Failure: Signifies need to change therapy; any of the
following criteria defines failure, whichever occurs first:11
Fresh hematemesis > 2 hours after start of specific drug
treatment or therapeutic endoscopy. In the minority of
patients, who have a nasogastric tube in place, aspiration
of greater than 100 ml of fresh blood represents failure.
3-g drop on hemoglobin (≈9% drop in Ht) if no
transfusion is administered.
Death.
Adjusted Blood Transfusion Requirement Index (ABRI)
> 0.75 at any time point.
ABRI= Blood units transfused
(Final Hematocrit - Initial Hematocrit) + 0.1
Hematocrit (or Hemoglobin) is measured at least every
6 hours for the first 2 days, and then every 12 hours for
days 3 - 5.
The transfusion target should be an hematocrit of 24%
or a hemoglobin of 8 g/dL.
Variceal rebleeding: Occurrence of new hematemesis
or melena after a period of 120 hours or more from time
zero (time zero is the time of admission to the first
hospital the patient is taken to). All bleeding episodes
regardless of severity should be counted in evaluating
rebleeding.12
Early mortality: Death within 6 weeks of the initial
episode of bleeding.9
Treatment of acute variceal bleeding: Ideally, the
patients with variceal bleeding should be treated in a unit
where the personnel are familiar with the management
of such patients and where routine therapeutic
interventions can be undertaken. Therapy is aimed at
correcting hypovolemic shock and at achieving
hemostasis at the bleeding site. Proper management of
such patients include: initial assessment, resuscitation,
blood volume replacement, vasoactive agents,
prevention of associated complications such as bacterial
infections, hepatic encephalopathy, coagulopathy and
thrombocytopenia, and specific therapy.
Initial assessment: History and physical examination
has pivotal role. On arrival of the patient, baseline
investigations must be sent to laboratory. These must
include Complete Blood Count (CBC), platelets count,
Prothrombin Time (PT), Liver Function Tests (LFTs),
urea and creatinine, serum electrolytes, glucose, blood
grouping and cross matching. Child-Turcotte-Pugh
(CTP) score should be calculated to classify the patient
accordingly. Additional tests to determine comorbidity
and prognosis include abdominal ultrasound (preferably
bedside, so shifting of the patient to radiology
department is not required), ECG in patients over > 45
years of age, and O2 saturation.
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Resuscitation of the patient: The most important step
in the management of variceal bleeding is to evaluate
the patient hemodynamically. If in shock, basic ABC
(passing airway, ensuring good breathing, and
maintaining circulation - pulse and blood pressure)
needs to be achieved before doing anything else.
Adequate resuscitation is achieved with pulse less than
100 per minute, systolic blood pressure more than 100
mm Hg, no postural drop, and O2 saturation more than
90%. At least 2 wide bore (16 G preferably) IV cannulae
should be passed and ideally 4 - 6 units of blood should
be arranged. Acute variceal bleeding is a medical
emergency that should be managed under intensive
care facilities by a team of experienced medical staff
including endoscopists, hepatologists, surgeons and
nurses. Minimum facilities in the unit should include
cardiac monitoring, ventilation, pulse oximetry and
infusion pumps. Endotracheal Tube (ET) intubation may
be considered in a patient if in shock, mental status
change, continuous heavy bleeding, and respiratory
compromise. Nasogastric (NG) tube may be placed in
selected patients with active bleeding for clearing the
field of vision and monitoring of continuous bleeding.
Balloon tamponade should only be used as a temporary
bridge by trained personnel until definitive treatment can
be instituted, for a maximum of 24 hours, and preferably
in an intensive care facility. It should be used in case of
massive bleeding, failure of therapy with active bleeding
and hemodynamic instability despite adequate
pharmacotherapy and endoscopic therapy.
Blood volume replacement: Blood volume restitution
should be done cautiously and conservatively, using
plasma expanders to maintain hemodynamic stability
and packed red blood cells to maintain the hemoglobin
at approximately 7-8 g/dl, depending on other factors
such as patient's co-morbidities, age, hemodynamic
status and presence of ongoing bleeding clinically.
Colloids may be used cautiously while awaiting
availability of blood and blood products. Over
transfusion should be avoided as this can increase
portal pressures and exacerbate further bleeding.
Vasoactive drugs: These are used to arrest bleeding by
decreasing pressure and blood flow within the
esophageal varices, thus, allowing hemostasis at the
bleeding points. Vasoactive drugs have been shown to
control acute variceal bleeding in about 80% of
patients.54-60 Vasoactive therapy can be used empirically
when variceal bleeding seems likely on clinical grounds.
The current recommendation is to start a vasoactive
agent as early as possible from the time of admission or
even upon the patient's transfer to the hospital.54,55 The
agents available are: Vasopressin (± Nitroglycerine) or
its analogue - Terlipressin, and Somatostatin or its
analogues - Octreotide and Vapreotide.
Vasopressin was the first vasoactive agent used in the
treatment of acute variceal bleeding. It has, however,
significant systemic side-effects which include
myocardial and mesenteric ischemia and infarction.61
The addition of Nitroglycerine to Vasopressin-enhances
its efficacy and reduces the cardiovascular side-
effects.62,63
Terlipressin, a synthetic vasopressin analogue with
fewer side-effects and a longer half-life than
vasopressin, is effective in controlling acute variceal
bleeding.64,65 Terlipressin is administered as intravenous
(IV) injections of 2 mg bolus and 1 mg every 4 - 6 hours
for 2-5 days. A meta-analysis demonstrated that
Terlipressin was associated with a 34% relative risk
reduction in mortality compared to placebo.64
Somatostatin and its synthetic analogues, Octreotide
and Vapreotide, control acute variceal bleeding in upto
80% of patients and are generally considered to be
equivalent to Terlipressin but superior to Vasopressin for
the control of acute variceal haemorrhage.64
Somatostatin is given as an IV 250 mcg bolus followed
by 250 mcg/hour infusion. Octreotide is administered as
a bolus injection of 100 mcg followed by an infusion at a
rate of 25 - 50 mcg/hour. Somatostatin or Octreotide
therapy should be maintained for 5 days to prevent early
rebleeding.
In acute variceal bleeding, Terlipressin may have an
added advantage as it can potentially reverse
hepatorenal syndrome.66 In addition, Terlipressin has
been shown to have a more sustained hemodynamic
effect compared to treatment with Octreotide.67
Octreotide and Terlipressin have been found to have
similar control of initial bleeding and similar risk of
rebleeding.68 Regarding duration of Terlipressin therapy,
24 hours has been found to be as effective as 72 hours,
when it is used in conjunction with EVBL.69
The use of intravenous proton pump inhibitors in this
setting needs further study before a recommendation
can be made.
Bacterial infections: Bacterial infections are seen in
about 20% of cirrhotics presenting with upper
gastrointestinal bleeding within 48 hours.70,71 The
incidence of sepsis increases to almost 66% at two
weeks.72-77 Development of bacterial infection is
associated with high mortality and variceal
re-bleeding.71,75 Antibiotic prophylaxis has been shown
to reduce the rate of infection, spontaneous bacterial
peritonitis and rebleeding.76-80 In addition, antibiotic
prophylaxis was clearly proven in a meta-analysis to
significantly increase the survival rate.81 Short-term
antibiotic prophylaxis for 7 days should be considered
the standard of care in cirrhotic patients with upper
gastrointestinal bleeding, irrespective of the type of
haemorrhage (variceal or non-variceal) or the presence
or absence of ascites. Either intravenous third
generation cephalosporins (Ceftriaxone) or oral
quinolones (Ciprofloxacin) are generally recommended.
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Hepatic encephalopathy: In patients who present with
or develop encephalopathy, this should be treated with
Lactulose or other drugs. There are no studies
evaluating the usefulness of lactulose for the prevention
of hepatic encephalopathy, but the committee feels that
it may be considered, if the treating physician wants so.
Coagulopathy and thrombocytopenia: Recom-
mendations regarding management of coagulopathy
and thrombocytopenia cannot be made on the basis of
currently available data, but it may be considered if a
platelets count is less than 50,000/cmm.
Specific therapy: As soon as the patient is
hemodynamically stable, endoscopy should be
performed; and if endoscopy is not available in the
center, he/she must be referred to the center where
endoscopy should be performed. Till endoscopy is
performed, vasoactive therapy should be continued as
stated earlier. Endoscopic therapy depends upon the
source of bleeding.
Esophageal varices: Endoscopic therapy includes
Endoscopic Injection Sclerotherapy (EIS) and
Endoscopic Variceal Band Ligation (EVBL). EIS stops
bleeding in 80-90% of patients with acute variceal
haemorrhage.82-84 EVBL is more effective than EIS in
controlling acute esophageal variceal bleeding, is
associated with fewer complications and a survival
advantage.85-88 Technically, EVBL may be difficult at
times because of limited visualization from bleeding and
EIS is used as it is easier to perform in this setting.
Administering vasoactive agents before endoscopic
therapy, facilitates endoscopy, improves control of
bleeding, transfusion requirements, and reduces 5-day
re-bleeding rate,89-92 but with no effect on mortality,93
both in low-risk and high-risk patients,94 and even if
administered just after the endoscopic procedure.95-97
Gastric varices: Endoscopic therapy depends upon the
type of gastric varices. GEV1 are treated as esophageal
varices. GEV2 and IGVs are treated with Injection of
Cyanoacrylate glue, which controls acute gastric
bleeding in 90% cases,98-100 better than alcohol and
band ligation.101,102 Histoacryl should be mixed with
Lipiodol in a ratio of 0.5:0.8 ml. After ensuring
intravariceal position of the needle, Histoacryl should be
injected in a slow and controlled fashion and should not
exceed 1 ml at any one site as there is a risk of
thrombotic complications including pulmonary
embolism. Histoacryl injection sclerotherapy must only
be performed by experienced endoscopist.
Balloon-occluded retrograde transvenous obliteration
(BRTO) has been introduced as a new method to treat
GV. BRTO, and is also effective and has the potential
benefit of increasing portal hepatic blood flow and,
therefore, may be an alternative for patients who may not
tolerate TIPS. However, BRTO obliterates spontaneous
portosystemic shunts, potentially aggravating portal
hypertension and its related complications. The role of
BRTO in the management of acute GV bleeding is
promising but it merits further evaluation.103
Patients in CTP class C without active bleeding, and
CTP class B with active bleeding at presentation, after
securing hemostasis with pharmacological and
endoscopic therapy, are at high-risk of rebleeding;
therefore, in these patients an early TIPS within 72 hours
(ideally ≤ 24 hours) has been found to improve survival
significantly.104,105
Treatment failures: Treatment failures may be of two
types: Rebleeding during the first 5 days may be
managed by a second attempt at endoscopic therapy. If
rebleeding is severe, PTFE-covered TIPS is likely the
best option.106
Persistent bleeding despite combined pharmacological
and endoscopic therapy is best managed by TIPS with
PTFE-covered stents.107,108 Balloon tamponade should
only be used in massive bleeding as a temporary bridge
until definitive treatment can be instituted (for a
maximum of 24 hours, preferably in an intensive care
facility).109 Uncontrolled data suggest that self-
expanding covered esophageal metal stents may be an
option in refractory esophageal variceal bleeding,
although further evaluation is needed.110-112 Emergency
surgical portocaval shunt (within 8 hours of onset of
bleeding) has been reported to be associated with
almost universal control of bleeding and a low mortality
over a 30-year period, further validation is also needed
here.113
Recommendations:
1. Resuscitation: (a) ICU management is recommended
(2;C); (b) ET intubation may be considered in a patient if
in shock, mental status change, continuous heavy
bleeding, and respiratory compromise (5;D); (c) NG tube
may be placed in selected patients with active bleeding
for clearing the field of vision and monitoring of
continuous bleeding (5;D); (d) Balloon tamponade
should only be used as a temporary bridge by trained
personnel until definitive treatment can be instituted, for
a maximum of 24 hours, and preferably in an intensive
care facility (5;D).
2. Blood volume replacement: (a) Blood volume
restitution should be done cautiously and conservatively,
using plasma expanders to maintain hemodynamic
stability and packed red blood cells to maintain the
hemoglobin at approximately 7 - 8 g/dl, depending on
other factors such as patient's co-morbidities, age,
hemodynamic status and presence of ongoing bleeding
clinically (1b;A); (b) Colloids may be used cautiously
while awaiting availability of blood and blood products
(5; D).
3. Vasoactive therapy: (a) In suspected variceal
bleeding, vasoactive drugs should be started as soon as
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possible, before endoscopy (1b; A); (b) The efficacy of
Terlipressin is equal to Octreotide as an adjunct therapy
for the control of esophageal variceal bleed and in-
hospital survival (1b; A); (c) In patients with esophageal
variceal bleeding, a 24-h course of Terlipressin is as
effective as a 72-h course when used as an adjunctive
therapy to successful EVBL (1b; A);     (d)
Pharmacological therapy alone may be acceptable in
circumstances where endoscopic facilities are not
available and patient has stopped bleeding with this
therapy. However, the patient should be referred for
endoscopy and definitive therapy (EVBL) as soon as
possible (1c; A); (e) At the primary care level,
pharmacological therapy should be started at the time of
initial contact with the patient (1c; A).
4. Bacterial infections: (a) Antibiotic prophylaxis is an
integral part of therapy for patients with cirrhosis
presenting with upper gastrointestinal bleeding
and should be instituted from admission (1a; A);
(b) Intravenous Ceftriaxone / Oral quinolones are
recommended for most patients (1b; A); (c) Intravenous
Ceftriaxone is preferable in hospital settings with high
prevalence of quinolone-resistant bacterial infections
and in patients on previous quinolone prophylaxis (5; D).
5. Hepatic encephalopathy: (a) Recommendations
regarding management and prevention of encephalo-
pathy in patients with cirrhosis and upper GI bleeding
cannot be made on the basis of currently available data
(5;D); (b) It is best left to the choice of caring physician
(5; D).
6. Coagulopathy and thrombocytopenia: (a) Recom-
mendations regarding management of coagulopathy
and thrombocytopenia cannot be made on the basis of
currently available data; anyhow, it may be considered if
a platelet count is less than 50,000 /cmm (5; D); (b)
PT/INR is not a reliable indicator of the coagulation
status in patients with cirrhosis (1b; A).
7. Specific therapy: (a) Patients with GI bleeding and
features suggesting cirrhosis should have upper
endoscopy as soon as possible after admission (within
12 h) after hemodynamic stabilization with airway control
(5-D); (b) Endoscopic therapy is recommended in any
patient who presents with documented upper GI
bleeding and in whom esophageal varices are the cause
of bleeding (1a;A); (c) Endoscopic Variceal Band
Ligation (EVBL) is the recommended form of endoscopic
therapy for acute esophageal variceal bleeding,
although Sclerotherapy may be used in the acute
setting, if ligation is technically difficult (1b;A); (d)
Endoscopic Injection Sclerotherapy (EIS) with tissue
adhesive (e.g. N-butyl-cyanoacrylate) is recommended
for acute bleeding from isolated gastric varices (IGV)
(1b;A) and those gastro-esophageal varices type 2
(GEV2) that extend beyond the cardia (5;D); (e) EVBL or
EIS with tissue adhesive can be used in bleeding from
gastroesophageal varices type 1 (GEV1) (4;C);
(f) Combination of pharmacological therapy and
endoscopic therapy is the most rational approach in the
treatment of acute variceal haemorrhage. (1;a A)
8. Early TIPSS: (a) An early TIPSS within 72 h (ideally
24 h) should be considered in patients at high-risk of
treatment failure (e.g. CTP class C <14 points or CTP
class B , or with active bleeding) after initial pharma-
cological and endoscopic therapy (1b;A); (b) HVPG
measurements may be helpful to select patients for early
TIPS
9. Treatment failures: (a) Refractory Bleeding -
Persistent bleeding despite combined pharmacological
and endoscopic therapy; (i) It is best managed by TIPS
with PTFE-covered stents (1b;A); (ii) Balloon tamponade
should only be used in massive bleeding as a temporary
''bridge” until definitive treatment can be instituted (for a
maximum of 24 h, preferably in an intensive care
facility); (iii) Surgery may be considered in the absence
of facilities for TIPS in selected patients (child A Cirrhosis
with acute, uncontrolled variceal bleeding (5-D);
(iv) Emergency surgical portocaval shunt (within 8 hours
of onset of bleeding) has been reported to be associated
with almost universal control of bleeding and a low
mortality over a 30-year period (5-D); (v) Uncontrolled
data suggest that self-expanding covered esophageal
metal stents may be an option in refractory esophageal
variceal bleeding, although further evaluation is needed
(4;C); (b) Re-bleeding during the first 5 days: (i) It may
be managed by a second attempt at endoscopic therapy
(2b;B); (ii) If re-bleeding is severe, PTFE-covered TIPSS
is likely the best option (2b;B)
Secondary prophylaxis of varices: Secondary
prophylaxis is the prevention of recurrent bleeding after
a first episode variceal bleed. All those patients, who
survive an episode of acute variceal bleed, have a high
risk of rebleeding. About 60% will rebleed within 2 years
with a mortality of 33%.95,25 Therefore, it is mandatory
that after successful recovery from acute variceal
bleeding episode, all patients must be started on therapy
to prevent recurrence of bleeding prior to discharge from
the hospital.22,114 Patients who require shunt surgery/
TIPSS to control the acute episode, do not require
further preventive measures. All these patients should
be referred to a transplant center, if they are otherwise a
candidate (i.e., CTP score ≥ 7 or a MELD score ≥ 15).
Definitions in the context of secondary prophylaxis:
The committee adopted following definitions of key
events in the context of secondary prophylaxis:
Timing: It should be started as soon as possible from
day 6 of the index variceal bleeding episode or at the
time of discharge. The time of start of secondary
prophylaxis should be documented.
Failure to prevent re-bleeding is defined as a single
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episode of clinically significant re-bleeding from portal
hypertensive sources after day 5.
Clinical significant re-bleeding is defined as recurrent
melena or hematemesis, resulting in any of the
following: hospital admission, blood transfusion, 3 g drop
in Hb, and death within 6 weeks.
Treatment modalities: Various modalities used for
secondary prophylaxis include pharmacological therapy,
endoscopic therapy with or without pharmacological
therapy, and TIPSS.
Pharmacological therapy: Secondary prophylactic
therapy with pharmacological therapy is based on the
assumption that a sustained reduction in portal pressure
reduces the incidence of variceal rebleeding. Non-
selective Beta Blockers (NSBB) with or without
Isosorbide Mononitrate (IM) have been widely studied in
the secondary prophylaxis of variceal bleeding.
Non-selective beta blockers monotherapy: NSBBs
are still the mainstay of pharmacotherapy.115-117 A meta-
analysis of 12 randomized controlled trials comparing
NSBB to either no treatment or placebo, showed a
statistically significant reduction in the risk of recurrent
bleeding and survival advantage.118 The incidence of
recurrent variceal bleeding was 42.7% in the placebo
group and 32% in the beta-blocker group, a reduction in
the risk of bleeding by one third, and mortality from 27%
to 20%.95,119
Non-selective Beta Blockers (NSBBs) treatment in
cirrhotic patients is an undisputed strategy for bleeding
prophylaxis. Nevertheless, recent studies question the
efficacy and safety of NSBBs in patient with advanced
cirrhosis, particularly in case of refractory ascites and
spontaneous bacterial peritonitis. According to a window
hypothesis,120 NSBBs are beneficial only in
decompensated patients with medium-large varices but
not in patients with early or end-stage cirrhosis with
refractory ascites. Data from a study performed by
Serstè et al.121 showed that mortality in patients with
refractory ascites was increased if taking NSBBs. The
same group hypothesized that β-blockade could induce
counter-regulatory over-activation of the Renin-
Angiotensin Aldosterone axis, increasing incidence of
paracentesis-induced circulatory dysfunction, which
could be associated with impaired renal function and
reduced survival.122 These data were not confirmed by
another study on patients with ascites taking
propranolol,123 moreover, by analyzing all published
randomized controlled trials on prophylaxis for variceal
hemorrhage, bleeding unrelated mortality was similar
between patients on NSBBs and those treated with other
therapies in primary (277/955 vs. 287/1175; OR 0.91
95% CI 0.73 - 1.15) and secondary prophylaxis
(188/1143 vs. 225/1208; OR 0.87 95% CI 0.68 - 1.12)
without heterogeneity amongst studies, while causes of
death were not different between patients on and off
NSBBs therapy. These results were confirmed in the
subgroup analysis of studies with higher prevalence of
ascites (> 50%).124 While a beneficial role of NSBB on
several outcomes in cirrhotic patients is well established,
the effect in patients with refractory ascites is still
unclear, and a possible harmful effect is under debate. A
potential harmful effect of propranolol in patients with
cirrhosis with refractory ascites deserves further
confirmation.
Non-selective beta blockers with isosorbide
mononitrate: Further reduction in portal pressure can
be achieved by adding ISMN.125 Some early RCTs and
systematic reviews suggested greater reduction in
rebleeding rates with combination pharmacological
therapy as compared to BB alone,25,95,119 strengthening
the impression that combination of BB and ISMN is the
therapy of choice in secondary prohylaxis. However,
according to local data and a recent meta-analysis, the
combination of NSBB and ISMN is not different from
NSBB alone regarding the rate of overall re-bleeding or
mortality, but has a higher rate of side-effects.126,127
Endoscopic therapy: Two types of endoscopic
therapies have been used in the secondary prophylaxis
of variceal bleeding: Endoscopic Injection Sclerotherapy
(EIS) and Endoscopic Variceal Band Ligation (EVBL).
The latter has almost replaced the former one.
Endoscopic injection sclerotherapy: It is performed
every 10 - 14 days until the varices are obliterated,
which typically requires 5 or 6 sessions. Sclerotherapy
decreases rebleeding rates and mortality as compared
to placebo,128 but is associated with serious compli-
cations (e.g., esophageal strictures, bleeding from
ulcers).
Endoscopic variceal band ligation: Sclerotherapy has
been replaced by EVBL, since it has significantly better
outcomes (rebleeding, mortality and side-effects)
compared with sclerotherapy.129-133 Similar to sclero-
therapy, EVBL is performed every 10 - 14 days until the
varices are eradicated, which usually takes 3 or 4
sessions.
Combination of EIS and EVBL: The addition of
sclerotherapy to ligation has not been shown to be
advantageous.134,135 A higher incidence of esophageal
stricture was noted in the group who had both EIS and
EVBL.136 A more recent meta-analysis confirmed earlier
reports that the combination of EIS and EVBL is not
superior to EVBL alone in reducing the risk of variceal
rebleeding, death or time to variceal obliteration.137
Pharmacological versus endoscopic therapy: Studies
comparing pharmacological therapy (NSBB plus ISMN)
vs. EVBL show no differences in recurrent haemorrhage,
but there is a suggestion of a beneficial effect on survival
with pharmacological therapy in the long term.127,138-141
In one study, the rebleeding rate was higher in the EVBL
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group as compared with pharmacological therapy (49%
vs. 33% respectively).142 The risk of recurrent bleeding
and of death is significantly lower in patients with
haemodynamic response to therapy (defined as a
reduction in the HVPG by more than 20% of the baseline
value or to less than 12 mmHg). Currently, there is not
enough evidence to support the use of the targeted
reduction of HVPG in routine clinical practice.143
Combined pharmacological and endoscopic
therapy: Two prospective trials found the combination of
EVBL with medical therapy (Nadolol) superior to EVBL
alone.144,145 Current recommendation is to use NSBB
and EVBL, after initial variceal bleeding, as a means of
secondary prophylaxis.22
TIPSS: In situations of recurrent variceal bleeding
despite combined endoscopic and pharmacological
therapy, TIPSS with polytetrafluoroethylene (PTFE)
covered stents,146 or where expertise is available,
surgical shunts147 should be provided.
HVPG: Incorporating HVPG in the secondary
prophylaxis of variceal bleeding is a relatively new
concept. The lowest rates of recurrent variceal
haemorrhage (approximately 10%) are observed in
individuals who have a hemodynamic response to
pharmacologic therapy, defined as a decrease in HVPG
to < 12 mmHg or a decrease of > 20% from baseline
levels.25,148 So in hemodynamic responders to
pharmacological therapy, endoscopic treatment would
not be necessary. The more rational approach would
thus be to guide therapy based on hemodynamic
response, however, a small trial showed that outcomes
with HVPG-guided therapy are not different from those
in patients treated with combined pharmacological and
endoscopic therapy.149 Until the best treatment for non-
responders is settled, larger clinical trials are performed,
and HVPG measurements are standardized across
centers, HVPG-guided therapy cannot be currently
recommended.150
Gastric varices: Rebleeding rates after an acute GV
bleeding episode treated with tissue adhesives (mainly
cyanoacrylate) range from 7% to 65% with most of the
large series reporting rates below 15%.103 Similar to
what occurs with initial hemostasis, cyanoacrylate (CA)
has been shown to be superior to both Sclerotherapy
and band ligation for secondary prophylaxis.103 On the
contrary, comparison with non-selective beta-blockers
offers conflicting results. In a small randomized study,
comparing repeated cyanoacrylate injections vs.
propranolol as secondary prophylaxis, no significant
differences were observed between the two groups in
the incidence of variceal rebleeding and death. The
incidence of complications was higher in the CA group
(47% vs. 10%).151 A major limitation of the study was the
small number of patients with GV. In a more recent RCT
comparing cyanoacrylate vs. propranolol as secondary
prophylaxis, rebleeding in the CA group was significantly
lower than in the beta-blocker group (15% vs. 55%,
p=0.004) and after a 26 months follow-up, the mortality
rate was lower as well (3% vs. 25%, p=0.026). The rate
of complications in the CA group was 3%.152 In a recent
study, patients with GV that bled and were successfully
treated with CA were assigned to receive treatment with
beta blockers and repeated CA injections or repeated
CA injections alone.153 The overall rebleeding and
survival rates, after a mean follow up of 19 months, were
not different between the two groups. One-year
rebleeding-free survival was also similar. The result of
this study suggests that adding beta blocker therapy to
repeated sessions of CA provides no important benefit
for prevention of rebleeding and mortality in patients with
GV bleeding. Despite these findings, and because non-
selective beta-blockers are effective in patients with
concomitant esophageal varices, until larger studies with
longer follow-up are available, non-selective beta-
blockers are still recommended as an adjunct to
endoscopic therapy in the prevention of GV
rebleeding.103
Thrombin is safe and effective in the treatment of acute
GV bleeding with hemostasis rates of 70 - 100%, given
the paucity of data mostly coming from case series,
the routine use of thrombin cannot be routinely
recommended for secondary prophylaxis of GV.103
TIPSS is a very effective therapy to prevent GV
rebleeding, but more data is needed to clarify the role of
TIPSS in the secondary prophylaxis of GV bleeding and
to determine if this therapy must be universally applied
or reserved as a rescue therapy after failure of more
conservative approaches.102
Surgery has fallen out of favour. In selected cases,
patients with gastric varices and segmental/left-sided
portal hypertension, due to isolated splenic vein
thrombosis, may be candidates for splenectomy or
splenic embolization as a means of definitive therapy,
however data is scarce.103
Although Balloon-occluded Retrograde Trans-venous
Obliteration (BRTO) seems to be a feasible technique,
able to successfully control and prevent GV bleeding,
there is a lack of good quality data to establish the actual
place of BRTO on the management of GV. BRTO
could be considered in patients with GV bleeding and
large gastrorenal shunts in whom TIPS may be
contraindicated (such as those with refractory hepatic
encephalopathy or elderly patients).103
Recommendations:
1. Candidates: (a) After the control of acute variceal
bleeding, secondary prophylaxis must be given to all
patients (1a, A); (b) Patients; who require shunt
surgery/TIPSS to control the acute episode, do not
require further preventive measures. All these patients
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should be referred to a transplant center, if they are
otherwise a candidate (i.e., CTP score ≥ 7 or a MELD
score ≥ 15) (1a, A).
2. Timing: (a) It should be started as soon as possible
from day 6 of the index variceal bleeding episode or at
the time of discharge (1a,A); (b) The time of start of
secondary prophylaxis should be documented (1a, A).
3. Modalities of therapy: (a) Combination of NSBB and
endoscopic variceal ligation is the treatment of choice for
secondary prophylaxis (1a, A); (b) If endoscopy is not
possible, BB alone or in combination with ISMN should
be given (1a; A); (c) If BB are contraindicated then EVL
is the preferred treatment (5; D).
4. Choice of β-blockers: (a) Propranolol and Nadolol
have been extensively studied; however, Carvedilol is an
emerging alternative. (b) Carvedilol may be started at a
dose of 6.25 mg daily and increased to 6.25 mg twice
daily, if clinically tolerated. Carvedilol is as effective as
Nadolol plus Isosorbide-5-Mononitrate in the prevention
of gastroesophageal variceal rebleeding with fewer
severe adverse events and similar survival (1b; A).
5. Endoscopic variceal band ligation: (a) EVBL
should be repeated every 2 - 4 weeks until obliteration
(1b, A); (b) Following successful eradication of varices,
patients should be endoscoped at 3 months and 6
monthly intervals thereafter, to look for recurrence of
varices (1b, A); (c) In case of recurrence, band ligation
should be repeated (1b, A).
6. Other modalities: (a) TIPSS may be considered in
child A or B patients who have recurrent variceal bleed
despite combination of pharmacological and endoscopic
therapy as secondary prophylaxis (2b; B); (b) Surgical
shunts may be considered in Child A/selected Child B
patients as an alternative, if TIPSS is unavailable (2b;
B); (c) Transplantation provides good long-term outcome
in appropriate candidates and should be considered
(2b; B); (d) TIPSS may be used as a bridge to
transplantation (4, C)
7. Gastric varices: (a) GEV1: Treatment of GEV 1 by
EVL or BB is sufficient. GEV1 may be treated with
cyanoacrylate injection (2b; B); (b) After the acute
episode; patients with GEV 2/IGV1 should receive beta
blockers along with repeated sessions of CA injection
(1b; A) or TIPSS (2b; B); (c) There is a lack of good
quality data to establish the actual place of BRTO in the
secondary prophylaxis bleeding from GV.
8. Portal hypertensive gastropathy: (a) BB should be
used for prevention of recurrent bleeding in portal
hypertensive gastropathy (1b,A).
Areas requiring further studies: The following areas
need further studies: incidence and natural history of
varices and variceal bleeding (local data needs to be
generated), non-invasive techniques to identify patients
with clinically significant portal hypertension, the impact
of treating the underlying chronic liver disease in the
development of varices and other portal hypertensive
related complications, treatments to prevent the
development of varices and other portal hypertensive
related complications, studies evaluating the use of
carvedilol in primary prophylaxis of variceal bleeding,
role of NG tube in the setting of acute variceal bleeding,
ICU and non-ICU management in resource-constrained
country, prophylaxis of PSE in the setting of acute
variceal bleeding, optimal duration of vasoactive drug
therapy, role of PPIs in the setting of acute variceal
bleeding, need for correction of coagulation disorders in
the setting of acute variceal bleeding. Influence of
coagulopathy and thrombocytopenia on outcome, better
stratification of risk to determine timing of the initial
endoscopy, duration of drug therapy and type of
treatment, best antibiotic in the setting of acute variceal
bleeding, role of self-expandable esophageal stents in
the setting of acute variceal bleeding, treatment of
gastric varices, treatment of pediatric patients, treatment
of bleeding ectopic varices like duodenal varices, role of
erythromycin before endoscopy, HVPG role in
secondary prophylaxis, carvedilol vs. propranolol in
secondary prophylaxis, beta-blocker alone or in
combination with CA for secondary prophylaxis in
GEV2/IGV1; and role of thrombin in secondary
prophylaxis in GEV2/IGV1.
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